LEPU BIO-B (02157) has announced a profit alert. The company expects its net profit attributable to shareholders for the fiscal year ending December 31, 2025, to be no less than RMB 200 million. This represents a significant turnaround compared to a loss of approximately RMB 411 million reported for the year ending December 31, 2024, indicating an improvement of no less than RMB 611 million.

This anticipated shift to profitability and substantial increase in net profit attributable to shareholders is primarily attributed to several key factors. The company achieved robust revenue growth driven by domestic commercialization efforts and licensing agreements. A significant portion of this revenue growth stemmed from the products Puyouheng (Putilimab Injection) and Meiyouheng (Vibecotumab Injection for Injection), with the latter generating initial revenue following its approval by the National Medical Products Administration in October 2025.

Furthermore, the company's profitability has been continuously enhanced through the expansion of its licensing transactions. These include the out-licensing of MRG007 and the out-licensing of CTM012 and CTM013, which are two of the company's preclinical TCE assets.

Additionally, during the year ending December 31, 2025, the company recognized a one-time gain. This gain resulted from the reclassification of one of its investments from an associate to an investment measured at fair value, a change prompted by the company no longer exerting significant influence over the investee company. It is important to note that this gain is non-recurring and non-operational in nature.